Bli medlem
Bli medlem

Du är här


Myriad Genetics, Inc.: Myriad Appoints Jan Schluchter as Chief Commercial Officer for Europe

Former Executive at Novartis Joins Myriad's International Leadership TeamSALT LAKE CITY and ZURICH, Switzerland, Oct. 1, 2015 (GLOBE NEWSWIRE) --
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in the personalized medicine
industry with innovative, high-quality molecular diagnostics, today announced
that Jan Schlüchter, Ph.D., has joined the Company as chief commercial
officer (CCO) of Myriad Genetics GmbH, effective Oct. 15, 2015. He will
report to Gary King, executive vice president, International Operations.

"Our international business represents a significant long-term growth
opportunity for Myriad and the European region is our biggest near-term
opportunity," said King. "We are delighted to welcome Jan Schlüchter as our
new chief commercial officer. His experience in leading and transforming
healthcare businesses will help us accelerate growth internationally."

Myriad Genetics GmbH is the Zurich-based international subsidiary of Myriad
Genetics, Inc. and oversees the international operations outside the United
States. As the CCO, Dr. Schlüchter will lead country operations in Europe to
drive new growth opportunities, offering superior molecular diagnostic
solutions for patients, physicians and payors. He will focus on
commercializing the Company's portfolio of hereditary cancer tests, companion
diagnostics and high-value test kits.

"I am excited to be joining an organization that is passionate about helping
patients make the right healthcare decisions with its pioneering molecular
diagnostics," said Dr. Schlüchter. "It is an exciting time at Myriad as the
company advances its pipeline and expands its commercial activities
internationally. Our goal is to make new leading molecular diagnostic
solutions accessible to all patients globally, and I am looking forward to
working with our key stakeholders."

Dr. Schlüchter has held several senior positions at Novartis over the past 12
years. Most recently he served as Global Head of Key Account Management at
Novartis' headquarters in Basel, Switzerland. Previously, he held General
Management roles in Greece and Germany. Before Novartis, Dr. Schlüchter was a
Consultant at McKinsey and has founded two companies. He received his
master's degree in management from the University of Nuremberg, Germany and
his doctor of philosophy degree in marketing from the University of Dortmund,

About Myriad Genetics GmbH

Myriad Genetics GmbH is the international subsidiary of Myriad Genetics, Inc.
It has established international headquarters in Zurich, Switzerland, a full
service laboratory in Munich, Germany and offices in Munich, Germany; Paris,
France; Madrid, Spain; Milan, Italy; London, UK; and Zurich, Switzerland.
Additionally, Myriad Genetics GmbH has a network of distributors worldwide.
For more information

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making
a difference in patients' lives through the discovery and commercialization
of transformative tests to assess a person's risk of developing disease,
guide treatment decisions and assess risk of disease progression and
recurrence. Myriad is focused on strategic directives to grow existing
markets, diversify through the introduction of new products, including
companion diagnostics, as well as to expand internationally. For more
information on how Myriad is making a difference, please visit the Company's

Myriad, the Myriad logo, BART, BRACAnalysis
, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice,
myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks
or registered trademarks of Myriad Genetics, Inc. in the United States and
foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
related to the hiring of Jan Schlüchter and the scope of his employment
responsibilities; and the Company's strategic directives under the caption
"About Myriad Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by
forward-looking statements. These risks and uncertainties include, but are
not limited to: the risk that sales and profit margins of our molecular
diagnostic tests and pharmaceutical and clinical services may decline; risks
related to our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related to
decisions or changes in governmental or private insurers' reimbursement
levels for our tests or our ability to obtain reimbursement for our new tests
at comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and services; the risk
that we may be unable to develop or achieve commercial success for additional
molecular diagnostic tests and pharmaceutical and clinical services in a
timely manner, or at all; the risk that we may not successfully develop new
markets for our molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying our
molecular diagnostic tests and pharmaceutical and clinical services and any
future tests and services are terminated or cannot be maintained on
satisfactory terms; risks related to delays or other problems with operating
our laboratory testing facilities and our healthcare clinic; risks related to
public concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the United States
and foreign countries and changes in the structure of the healthcare system
or healthcare payment systems; risks related to our ability to obtain new
corporate collaborations or licenses and acquire new technologies or
businesses on satisfactory terms, if at all; risks related to our ability to
successfully integrate and derive benefits from any technologies or
businesses that we license or acquire; risks related to our projections about
our business, results of operations and financial condition; risks related to
the potential market opportunity for our products and services; the risk that
we or our licensors may be unable to protect or that third parties will
infringe the proprietary technologies underlying our tests; the risk of
patent-infringement claims or challenges to the validity of our patents or
other intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit brought against
us by the Association for Molecular Pathology et al; risks of new, changing
and competitive technologies and regulations in the United States and
internationally; and other factors discussed under the heading "Risk Factors"
contained in Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2015, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors filed from
time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. All information in this press release is as of the date of the release,
and Myriad undertakes no duty to update this information unless required by

CONTACT: Media Contact:
Ron Rogers
(801) 584-3065

Investor Contact:
Scott Gleason
(801) 584-1143


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Myriad Genetics, Inc. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.